
Opinion|Videos|January 1, 2025
Discussing Seladelpar as a Potential Therapeutic for PBC
Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Seladelpar has been studied extensively, with the
RESPONSE trial serving as one of its landmark studies. What are the key efficacy findings from this trial?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
4
Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer
5










































































































































































































